Table 3 Cox regression predicting mortality risk for Women With Stage IV Breast Cancer (univariable and multivariable)
From: Could local surgery improve survival in de novo stage IV breast cancer?
Characteristic | Univariable HR*(95%CI) | P | Multivariable HR*(95%CI) | P |
|---|---|---|---|---|
Surgery | ||||
Yes vs No | 0.56(0.382-0.820) | 0.003 | 0.53(0.36-0.78) | 0.001 |
Viscera metastasis | ||||
Yes vs no | 1.73 (1.18-2.54) | 0.005 | ||
Bone metastasis | ||||
Yes vs no | 0.91 (0.62-1.32) | 0.610 | ||
CNS metastasis | ||||
Yes vs no | 1.40 (0.44-4.43) | 0.566 | ||
Soft tissue metastasis | ||||
Yes vs no | 0.99 (0.68-1.46) | 0.977 | ||
Age | ||||
≤50 vs >50 | 0.65 (0.44-0.95) | 0.026 | ||
Menopause status | ||||
Menopause vs menses | 1.21 (0.82-1.77) | 0.344 | ||
Biopsy | ||||
mass resection | 1§ | 0.753 | ||
core needle | 1.32 (0.64-2.73) | 0.457 | ||
fine needle | 1.43 (0.18-11.59) | 0.736 | ||
Histology | ||||
ductal | 1§ | 0.824 | ||
lobular | 0.66 (0.16-2.69) | 0.563 | ||
others | 1.11 (0.41-3.05) | 0.835 | ||
Tumor size | ||||
>5 cm vs ≤5 cm | 1.00 (0.67-1.49) | 0.981 | ||
Lymph node involvement | ||||
N0 | 1§ | 0.259 | ||
N1 | 2.48 (1.00-6.11) | 0.049 | ||
N2 | 1.95 (0.80-4.74) | 0.142 | ||
N3 | 2.14 (0.91-5.05) | 0.081 | ||
HER2 receptor status | ||||
Amplified | 1§ | 0.557 | ||
No-amplified | 0.81 (0.55-1.21) | 0.304 | ||
Not known or equivocal(2+) | 0.77 (0.31-1.93) | 0.574 | ||
Hormone receptor status | ||||
+ vs - | 0.49 (0.321-0.7233) | <0.001 | 0.57 (0.36-0.89) | 0.013 |
No. of metastasis sites | ||||
>3 vs ≤3 | 1.751 (0.881-3.477) | 0.11 | ||
Endocrine therapy$ | ||||
Yes vs no | 0.45 (0.30-0.68) | <0.001 | 0.55 (0.35-0.86) | 0.009 |
Anti-HER2 therapy$ | ||||
No | 1§ | 0.11 | ||
Yes | 0.54 (0.325-1.008) | 0.035 | ||
Unknown | 0.00 (0.00-5.357E+159) | 0.959 | ||
Radiotherapy | ||||
No | 1§ | 0.029 | ||
Yes | 0.61 (0.40-0.94) | 0.025 | ||
Unknown | 1.35 (0.71-2.57) | 0.357 | ||